all the latest information in
, arranged by experts and health care professionals. Listed below are recently added expert opinions.
How should genomic assessment in MF be performed?
Interview with Raajit K. Rampal during SOHO 2020 about how genomic assessment should be performed in patients with myelofibrosis.
How can outcome after transplant be improved for patients with MPN?
Interview with Uday R. Popat, MD Anderson Cancer Center, Houston, US on how to improve outcomes after transplant for patients with...
How would you manage a mildly symptomatic middle-aged woman with INT-1 primary myelofibrosis?
Interview with Uday Popat, MD Anderson Cancer Center, on how he would manage a mildly symptomatic...
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...
What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University...
Should we treat asymptomatic (‘early’) myelofibrosis with JAKi?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee member, Ruben A. Mesa, UT Health San...
Understanding the pathology of MPN: The value of in vivo and in vitro models
Among chronic Philadelphia-negative myeloproliferative neoplasms (MPN), polycythemia vera (PV) is considered the most...
Ruxolitinib discontinuation syndrome in patients with myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor that is licensed for the treatment of patients with myelofibrosis (MF) and is...
Alessandro M. Vannucchi
Haifa Kathrin Al-Ali
Jacqueline S. Garcia
Raajit K. Rampal
Ruben A. Mesa